PLGA-Based Nano-Adjuvant Boosts Mucosal and Systemic Immunity in Avian Influenza Vaccination

Study Background and Research Question

The persistent challenge of controlling H9N2 avian influenza virus (AIV) in poultry has underscored the limitations of current vaccine adjuvants, which often fail to induce robust mucosal immunity. The virus primarily invades avian hosts via the respiratory and digestive tracts, with subsequent dissemination linked to intestinal colonization and fecal shedding. While inactivated and live attenuated vaccines can elicit strong humoral and cellular responses, their inability to trigger effective mucosal immunity, particularly in the intestinal tract, remains a critical weakness. Consequently, there is a pressing need for advanced adjuvant systems that can enhance mucosal and systemic immune responses, thereby improving overall vaccine efficacy against H9N2 AIV (Muhetaer et al., 2026).

Key Innovation from the Reference Study

The study led by Muhetaer and colleagues introduces a novel double-layered nanoparticle adjuvant—PEI-LSP-RA-PLGA—which incorporates Lagenaria siceraria polysaccharide (LSP) and retinoic acid (RA) into PLGA nanoparticles modified with polyethylenimine (PEI). This design leverages the biocompatibility and sustained release characteristics of PLGA, while the PEI modification enhances cellular uptake and intestinal targeting. The innovation lies in the adjuvant’s ability to co-deliver hydrophilic and hydrophobic agents and in its demonstrated capacity to direct immune activation toward the intestinal mucosa, a critical site for defending against enteric and respiratory pathogens (Muhetaer et al., 2026).

Methods and Experimental Design Insights

The PEI-LSP-RA-PLGA nanoadjuvant was synthesized using a double-emulsion (W1/O/W2) method, enabling the encapsulation of both water- and lipid-soluble immunomodulators. Particle size (approximately 200 nm) and positive zeta potential (+13 mV) were optimized for stability and mucosal transport. The nanoadjuvant was evaluated in vivo by immunizing chicks with inactivated H9N2 vaccine formulations containing PEI-LSP-RA-PLGA. Immunological assays measured serum IgG, intestinal IgA, cytokine profiles, and the functional status of immune organs. In vivo imaging was employed to track antigen release and tissue targeting, while gene expression analyses clarified the molecular mechanisms underpinning intestinal immune activation.

Protocol Parameters

• Nanoadjuvant composition: PLGA nanoparticles with PEI surface modification, encapsulating LSP and RA.
• Particle size: ~200 nm; optimized for mucosal uptake.
• Zeta potential: +13 mV for enhanced stability and cell interaction.
• Immunization schedule: Single administration with inactivated H9N2 vaccine; antigen release sustained up to 21 days.
• Endpoints: Quantification of serum IgG and intestinal IgA, cytokine secretion, immune organ indices, and imaging-based antigen distribution.

Core Findings and Why They Matter

The PEI-LSP-RA-PLGA nano-adjuvant markedly enhanced both systemic and mucosal immunity in the vaccinated chicks. Key findings include:

• Serum IgG levels increased by 132.83% over controls, indicating robust systemic immune activation.
• Intestinal IgA production rose by 115.12%, reflecting potent stimulation of mucosal immunity—critical for blocking viral entry and colonization (Muhetaer et al., 2026).
• Sustained antigen release at the injection site lasted 21 days, supporting prolonged immune stimulation.
• Intestinal targeting was validated by in vivo imaging and an increased density of IgA+ cells in the gut.
• Mechanistic studies revealed that the adjuvant exploits CCR9/CCR6 signaling, mediated by CCL20 and CCL25 chemokines, to direct immune cells to the intestine. Subsequent activation of Toll-like and NOD-like receptor pathways, as well as the IgA immune network, drives effective mucosal responses.

These findings demonstrate, for the first time, that a PLGA-based nano-adjuvant can simultaneously orchestrate long-term systemic and mucosal immunity in a poultry model, addressing a major gap in avian vaccine technology.

Comparison with Existing Internal Articles

Internal research resources highlight the importance of robust, reproducible detection platforms in immunological studies, particularly where protein and peptide labeling and high-sensitivity fluorescence imaging are required. For instance, articles such as "Sulfo-Cy5 Carboxylic Acid: Elevating Fluorescence Imaging Workflows" and "Sulfo-Cy5 carboxylic acid empowers life science researchers with unmatched water solubility and reduced fluorescence quenching" discuss the value of hydrophilic, quenching-resistant fluorescent dyes for tracking molecular events in complex biological systems. While these articles focus on the technical advantages of advanced dyes such as Sulfo-Cy5 carboxylic acid in fluorescence imaging and protein/peptide labeling, the reference study illustrates the practical immunological outcomes that can be interrogated using such detection tools. Improved mucosal immune responses—such as enhanced IgA production—can be directly visualized and quantified using high-sensitivity fluorescent dyes, bridging the gap between immunoengineering and detection technologies.

Limitations and Transferability

Despite the promising results, some limitations should be considered. The study was performed in a chick model; extrapolation to other avian species or mammals requires further validation. While the nano-adjuvant formulation demonstrated good stability and biocompatibility in the tested context, potential scale-up, long-term safety, and regulatory considerations for field deployment remain to be addressed. Furthermore, the mechanistic insights are robust within the studied system but may be influenced by species-specific immune architectures or microbiota compositions.

Research Support Resources

To facilitate similar immunological and fluorescence imaging workflows—such as tracking protein and peptide distribution or quantifying immune responses—researchers may employ Sulfo-Cy5 carboxylic acid (SKU A8137). This sulfonated hydrophilic fluorescent dye offers high water solubility and reduced fluorescence quenching, making it suitable for labeling proteins and peptides under fully aqueous conditions. It has proven utility in neuroscience and immunological research, including applications requiring excitation at 646 nm and emission at 662 nm. For best results in protein and peptide labeling, the pre-activated NHS ester variant is recommended. Used appropriately, Sulfo-Cy5 carboxylic acid supports sensitive and quantitative fluorescence-based detection—an asset for studies examining mucosal immunity or nanoparticle biodistribution. For further workflow guidance, see this internal review on dye selection for immunological imaging.